🟢 Korro Bio is trading 6.4% up today after narrower net loss

Korro Bio is trading 6.4% up now at $12.89 after August 6, 2026 earnings highlighted a narrower $18.9 million net loss.

• Cash totaled $137.9 million, with operating runway into the second half of 2028.
• KRRO-121 remains on track for first-in-human testing in the second half of 2026 and received European Orphan Drug Designation.
• KRRO-111 was nominated for alpha-1 antitrypsin deficiency, reinforcing the pipeline pivot; biotech-sector strength may have added support.